Literature DB >> 11557019

Investigation of the cellular uptake of E-Selectin-targeted immunoliposomes by activated human endothelial cells.

S Kessner1, A Krause, U Rothe, G Bendas.   

Abstract

In the present study the cellular uptake of targeted immunoliposomes by interleukin-1 activated human endothelial cells has been analysed by several spectroscopical and microscopical fluorescence techniques. Previous in vitro experiments demonstrated that the targeting of immunoliposomes to vascular selectins is a potential way for a selective drug delivery at inflammatory sites. In attempts to further adapt the targeting experiments to physiological conditions, we demonstrate that E-Selectin-directed immunoliposomes are able to bind their target cells under the simulated shear force conditions of capillary blood flow cumulatively for up to 18 h. In order to consequently follow the fate of liposomes after target binding, we analysed the route and degree of liposome internalization of the cells concentrating on cell activation state or various liposomal parameters, e.g., sterical stabilization, type of antibody or antibody coupling strategy. The use of NBD-labelled liposomes and subsequent fluorescence quenching outside the cells with dithionite show that circa 25% of the targeted immunoliposomes were internalized. According to inhibition experiments with agents that interfered with the endocytotic pathway, we found out that the major mechanism of liposome entry is endocytic. The entry involves, at least in part, receptor-mediated endocytosis via E-Selectin, a liposome accumulation in the endosomes and their acidification was proved by pyranine spectroscopic results. Furthermore, microscopical investigations demonstrate that also a fusion of liposomes with the cell membrane occurs followed by a release of entrapped calcein into the cytoplasm. These observations gain insight into the behaviour of E-Selectin-targeted immunoliposomes and indicate that these immunoliposomes have great potential to be used as drug carriers for intracellular drug delivery at inflammatory sites.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557019     DOI: 10.1016/s0005-2736(01)00368-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  22 in total

Review 1.  Endothelial nanomedicine for the treatment of pulmonary disease.

Authors:  Jacob S Brenner; Colin Greineder; Vladimir Shuvaev; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2014-11-14       Impact factor: 6.648

Review 2.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

3.  Preparation of cationic immunovesicles containing cationic Peptide lipid for specific drug delivery to target cells.

Authors:  Takuya Sugahara; Shinichi Kawashima; Akiko Oda; Yoshio Hisaeda; Keiichi Kato
Journal:  Cytotechnology       Date:  2005-01       Impact factor: 2.058

4.  Kinetic analysis of nanoparticulate polyelectrolyte complex interactions with endothelial cells.

Authors:  Sean M Hartig; Rachel R Greene; Gianluca Carlesso; James N Higginbotham; Wasif N Khan; Ales Prokop; Jeffrey M Davidson
Journal:  Biomaterials       Date:  2007-05-03       Impact factor: 12.479

Review 5.  The Future of Nanoparticle-Directed Venous Therapy.

Authors:  Benjamin Jacobs; Chandu Vemuri
Journal:  Semin Intervent Radiol       Date:  2017-03       Impact factor: 1.513

6.  Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells--a potential tool for specific drug delivery.

Authors:  Manuela Voinea; Ileana Manduteanu; Elena Dragomir; Monica Capraru; Maya Simionescu
Journal:  Pharm Res       Date:  2005-08-13       Impact factor: 4.200

Review 7.  Targeting antioxidant and antithrombotic biotherapeutics to endothelium.

Authors:  Ronald Carnemolla; Vladimir V Shuvaev; Vladimir R Muzykantov
Journal:  Semin Thromb Hemost       Date:  2010-05-20       Impact factor: 4.180

Review 8.  Targeted delivery of therapeutics to endothelium.

Authors:  Eric Simone; Bi-Sen Ding; Vladimir Muzykantov
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

9.  Discovery of a potent nanoparticle P-selectin antagonist with anti-inflammatory effects in allergic airway disease.

Authors:  Alison E John; Nicholas W Lukacs; Aaron A Berlin; Aiyappa Palecanda; Robert F Bargatze; Lloyd M Stoolman; Jon O Nagy
Journal:  FASEB J       Date:  2003-10-16       Impact factor: 5.191

10.  Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide.

Authors:  Ashish Garg; Alison W Tisdale; Eman Haidari; Efrosini Kokkoli
Journal:  Int J Pharm       Date:  2008-09-19       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.